Novel |
MYOD1 |
myogenic differentiation 1 |
- Myogenesis
- Myogenesis
- TGFBR3 expression
|
|
|
Novel |
NCF1 |
neutrophil cytosolic factor 1 |
- ROS and RNS production in phagocytes
- Cross-presentation of particulate exogenous antigens (phagosomes)
- Detoxification of Reactive Oxygen Species
- VEGFA-VEGFR2 Pathway
- RHO GTPases Activate NADPH Oxidases
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RAC3 GTPase cycle
|
|
- Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
|
Novel |
NCOA6 |
nuclear receptor coactivator 6 |
- BMAL1:CLOCK,NPAS2 activates circadian expression
- PPARA activates gene expression
- PPARA activates gene expression
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Transcriptional regulation of white adipocyte differentiation
- Regulation of lipid metabolism by PPARalpha
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Cytoprotection by HMOX1
- Heme signaling
- Formation of WDR5-containing histone-modifying complexes
- Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
- RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
|
|
|
Novel |
NDC80 |
NDC80 kinetochore complex component |
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- RHO GTPases Activate Formins
- Mitotic Prometaphase
- EML4 and NUDC in mitotic spindle formation
|
|
|
Novel |
NEFM |
neurofilament medium chain |
|
|
|
Novel |
ORC1 |
origin recognition complex subunit 1 |
- E2F-enabled inhibition of pre-replication complex formation
- Activation of ATR in response to replication stress
- Assembly of the ORC complex at the origin of replication
- CDC6 association with the ORC:origin complex
- Assembly of the pre-replicative complex
- Orc1 removal from chromatin
- Activation of the pre-replicative complex
- G1/S-Specific Transcription
|
|
- Patella dysplasias, including: Small patella syndrome (SPS); Nail-patella syndrome; Ear-patella-short statute syndrome
|
Novel |
PA2G4 |
proliferation-associated 2G4 |
|
|
|
Novel |
PAX2 |
paired box 2 |
- Formation of intermediate mesoderm
- Formation of the nephric duct
- Formation of the ureteric bud
|
|
- Renal coloboma syndrome (RCS); Papillorenal syndrome
|
Novel |
PAX5 |
paired box 5 |
- RUNX1 regulates transcription of genes involved in BCR signaling
|
|
- Lymphoplasmacytic lymphoma
|
Novel |
PAX6 |
paired box 6 |
- Regulation of gene expression in beta cells
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
- Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Formation of the anterior neural plate
|
|
- Ocular coloboma, including: Coloboma of iris choroid and retina (COI); Coloboma of optic nerve (COLON)
- Aniridia
- Polymicrogyria; Bilateral frontal polymicrogyria (BFP); Bilateral frontoparietal polymicrogyria (BFPP); Bilateral perisylvian polymicrogyria (BPP); Bilateral parasagittal parieto-occipital polymicrogyria (BPOP); Bilateral generalised polymicrogyria (BGP); Unilateral Polymicrogyria (ULP)
|
Novel |
PCDHB5 |
protocadherin beta 5 |
|
|
|
Novel |
PELP1 |
proline, glutamate and leucine rich protein 1 |
- Major pathway of rRNA processing in the nucleolus and cytosol
- PTK6 Expression
|
|
|
Novel |
PHB1 |
prohibitin 1 |
- RAF activation
- Signaling by moderate kinase activity BRAF mutants
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Processing of SMDT1
- Signaling downstream of RAS mutants
|
- Rocaglamide
- Didesmethylrocaglamide
|
|
Novel |
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K events in ERBB4 signaling
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- GAB1 signalosome
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- PI3K events in ERBB2 signaling
- PI3K/AKT activation
- Signaling by ALK
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- GP1b-IX-V activation signalling
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- RET signaling
- RHOA GTPase cycle
- Extra-nuclear estrogen signaling
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOV GTPase cycle
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- RHOF GTPase cycle
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Activated NTRK3 signals through PI3K
- FLT3 Signaling
- FLT3 Signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- RND3 GTPase cycle
- RND2 GTPase cycle
- RND1 GTPase cycle
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Signaling by LTK in cancer
- Signaling by LTK
- Co-stimulation by ICOS
|
- SF1126
- Enzastaurin
- Wortmannin
|
|
Novel |
PIK3R3 |
phosphoinositide-3-kinase regulatory subunit 3 |
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- Constitutive Signaling by Aberrant PI3K in Cancer
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RET signaling
- Extra-nuclear estrogen signaling
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Co-stimulation by ICOS
|
|
|
Novel |
PLA2G12A |
phospholipase A2 group XIIA |
- Acyl chain remodelling of PC
- Acyl chain remodelling of PS
- Acyl chain remodelling of PE
- Acyl chain remodelling of PI
- Acyl chain remodelling of PG
- Synthesis of PA
|
|
|
Novel |
PML |
PML nuclear body scaffold |
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of ubiquitinylation proteins
- Regulation of TP53 Activity through Acetylation
- Interferon gamma signaling
- Regulation of RUNX1 Expression and Activity
- Regulation of PTEN localization
- HCMV Early Events
|
|
- Acute myeloid leukemia (AML)
|
Novel |
POLA1 |
DNA polymerase alpha 1, catalytic subunit |
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Polymerase switching on the C-strand of the telomere
- Telomere C-strand synthesis initiation
- DNA replication initiation
- Activation of the pre-replicative complex
- Polymerase switching
- Removal of the Flap Intermediate
- Processive synthesis on the lagging strand
- G1/S-Specific Transcription
- Defective pyroptosis
|
- Cladribine
- Clofarabine
- Fludarabine
- Nelarabine
|
|
Novel |
PPARG |
peroxisome proliferator activated receptor gamma |
- PPARA activates gene expression
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- MECP2 regulates transcription factors
- Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
|
- alpha-Linolenic acid
- Icosapent
- Troglitazone
- Mesalazine
- Valproic acid
- Indomethacin
- Rosiglitazone
- Fenoprofen
- Nateglinide
- Clofazimine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Amiodarone
- Pioglitazone
- Mitiglinide
- Bezafibrate
- Flufenamic acid
- Resveratrol
- Phthalic Acid
- Capric acid
- Doconexent
- Oleic Acid
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- Reglitazar
- Elafibranor
- AMG-131
- CLX-0921
- Muraglitazar
- Ertiprotafib
- Ragaglitazar
- Tesaglitazar
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- 9(S)-HODE
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- Indeglitazar
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- Triclosan
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- Aleglitazar
- Clinofibrate
- Cannabidiol
- Lobeglitazone
- Ciglitazone
- Dexibuprofen
- Omega-3 fatty acids
- Curcumin
- Arhalofenate
- Isoflavone
- Naveglitazar
- Fenofibric acid
- Fish oil
- Medical Cannabis
- Nabiximols
- Darglitazone
- Curcumin sulfate
|
- Thyroid cancer
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Type II diabetes mellitus
|
Novel |
PPIA |
peptidylprolyl isomerase A |
- Platelet degranulation
- Uncoating of the HIV Virion
- Budding and maturation of HIV virion
- Integration of provirus
- Early Phase of HIV Life Cycle
- Minus-strand DNA synthesis
- Plus-strand DNA synthesis
- Binding and entry of HIV virion
- Assembly Of The HIV Virion
- APOBEC3G mediated resistance to HIV-1 infection
- Calcineurin activates NFAT
- Basigin interactions
- Neutrophil degranulation
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
- SARS-CoV-1 activates/modulates innate immune responses
|
- Cyclosporine
- Proline
- (3r)-1-Acetyl-3-Methylpiperidine
- Ethyl Oxo(Piperidin-1-Yl)Acetate
- Sanglifehrin A
- Copper
- Artenimol
|
|